Tarighi Shahriar, Kumari Poonam, Vaquero Alejandro, Braun Thomas, Ianni Alessandro
Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany.
Chromatin Biology Laboratory, Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain.
Mol Cell Oncol. 2024 Jul 17;11(1):2381287. doi: 10.1080/23723556.2024.2381287. eCollection 2024.
The nucleolar enzyme sirtuin 7 (SIRT7) promotes cancer progression in certain malignancies, likely in part by controlling ribosome biosynthesis. Recently, we discovered that SIRT7 destabilizes the cyclin dependent kinase inhibitor 2A (CDKN2A, known as ARF) within the nucleolus, aiding cancer progression. We propose that targeting nucleolar SIRT7 offers promise for new anti-cancer therapies.
核仁酶沉默调节蛋白7（SIRT7）在某些恶性肿瘤中促进癌症进展，可能部分是通过控制核糖体生物合成来实现的。最近，我们发现SIRT7会使核仁中的细胞周期蛋白依赖性激酶抑制剂2A（CDKN2A，也称为ARF）不稳定，从而促进癌症进展。我们认为，靶向核仁中的SIRT7有望带来新的抗癌疗法。
